AUSTIN, Tex., Sept. 14, 2011 /PRNewswire/ --Fred Ueland, M.D., Associate Professor of Gynecologic Oncology at the University of Kentucky‘s Markey Cancer Center, and principal investigator of the multi-center OVA1 clinical trial, today presented data demonstrating the improvement in sensitivity when using imaging in conjunction with OVA1. These data were highlighted at the 17th Annual European Society of Gynecologic Oncology (ESGO) meeting being held in Milan from September 11th to 14th.
The key finding from Dr. Ueland’s presentation is that OVA1, when combined with imaging, achieved 98.1% sensitivity for all types of ovarian cancers and obtained a negative predictive value (NPV) of 96.3%. Also, a rising OVA1 score correlated with an increasing risk of ovarian malignancy.
“Studies show that women have more favorable outcomes when surgery for ovarian cancer is performed by a gynecologic oncologist,” explained Dr. Ueland. “The current research demonstrates that OVA1 in conjunction with imaging will not only help identify more women with ovarian cancer for referral, but can give them greater confidence that their ovarian tumor is benign.”
“Because of the high mortality from ovarian cancer, clinical sensitivity for malignancy is a key metric, especially in the early stages when survival beyond five years is at its greatest,” said Gail S. Page, Chair and Chief Executive Officer of Vermillion, Inc. “These data further confirm and support the clinical utility of OVA1 as an adjunctive tool to aid physicians in the assessment of women with an adnexal mass.”
About Vermillion:
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women’s health. Additional information about Vermillion can be found at www.vermillion.com.
Forward-Looking Statement:
Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion’s plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion’s ability to protect and promote its proprietary technology; (2) Vermillion’s lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion’s stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion’s filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion’s expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.
This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC’s Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov.
SOURCE Vermillion, Inc.
